SLC1A3 and neoplasm: Decreased aspartate availability, due to inhibition of EAAT1 (SLC1A3) (system AG-), an aspartate/glutamate transporter, has been suggested to increase the vulnerability of tumor cells under low oxygen (Garcia-Bermudez et al., 2018).